Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Delcath Systems Inc

DCTH ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Medical Equipment, Supplies & Distribution ·

USA Small Cap Analyst: BUY

Last Close

$16.73

▼ -3.63%

Market Cap $580.51M · Vol 195.71K

Key Metrics

P/E Ratio

2,738.13

FWD: N/A

Market Cap

$580.51M

Small Cap

Div Yield

N/A

EPS Growth

-788.57%

YoY

RSI (14)

77.25

Momentum

Beta

0.63

vs Market

52W High

$17.41

3.91% below

52W Low

$8.12

106.03% above

Volume

195.71K

Avg 193.03K

P/B

3.15

Price-to-book

ROE

N/A

Return on equity

Free Float

91.80%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Delcath Systems Inc (DCTH) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does DCTH pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+10.72%

+27.32%

+45.99%

+79.70%

YTD

+65.64%

+59.79%

+195.06%

+82.64%

Financials & Valuation

TTM · Annual

Total Revenue	$85.23M
Net Income	$2.70M
Revenue Growth (YoY)	+20.60%
Gross Margin	86.16%
Operating Margin	0.77%
Net Profit Margin	3.17%
ROE	N/A
ROA · ROIC	3.51% · 3.00%

P/E Ratio	2,738.13
Forward P/E (FY1)	N/A
PEG Ratio	1.39
P/S	4.73
P/B	3.15
P/FCF	19.23
EPS Growth	-788.57%
Outstanding Shares	34.70M

Technical Indicators

50-Day SMA	$12.93
200-Day SMA	$10.69
RSI (14)	77.25
Beta	0.63
52-Week High	$17.41
52-Week Low	$8.12

Volume Today	195.71K
Avg Daily Volume (30D)	193.03K
Relative Volume	1.01x
Volatility (10D)	111.80
Volatility (30D)	75.06
Free Float	91.80%

Analyst Consensus

BUY

Current Price $16.73

Mean Target $24.50

52W Low$8.12 52W High$17.41

Current

Target

$8.12 $17.41

Current Analyst target

+46.44% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S81551

ISINUS24661P8077

CountryUnited States of America

Sub-IndustryMedical Prosthetics

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

STMN.S Straumann Holding AG +0.29% SOON.S Sonova Holding AG +0.92% COH.AX Cochlear Ltd -0.25% OBCK.DE Ottobock SE & Co KgaA +0.00% 6699.HK Angelalign Technology Inc +0.00%

Company Profile

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).